Bayer AG is to sell its animal health unit to the Eli Lilly & Co. spin off, Elanco, in a cash and stock transaction to the tune of $7.6bn as the German conglomerate repositions itself towards life sciences.
The deal, announced on 20 August, will improve Bayer’s ability to pay off some of the debt built up from...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
